For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260505:nRSE1031Da&default-theme=true
RNS Number : 1031D RELX PLC 05 May 2026
5 May 2026
RELX PLC
Transactions in own shares
RELX PLC announces that during the period 27 April 2026 to 1 May 2026 it
purchased through J.P. Morgan Securities plc a total of 3,111,937 RELX PLC
ordinary shares of 14 (51)/(116) pence each on the London Stock Exchange. The
purchased shares will be held as treasury shares.
RELX PLC
Transaction details: RELX PLC ordinary shares of 14 (51)/(116) pence each
Issuer name: RELX PLC
ISIN: GB00B2B0DG97
Intermediary name: J.P. Morgan Securities plc
Intermediary Code: JPMSGB2L
Time zone: UTC
Currency: GBP
Aggregated information
Date of purchase Number of ordinary shares purchased Highest price paid (p) Lowest price paid (p) Volume weighted average price paid per share (p)
27/04/2026 619,500 2723 2667 2697.6082
28/04/2026 616,000 2690 2648 2674.0217
29/04/2026 625,000 2663 2621 2644.6936
30/04/2026 628,437 2717 2640 2683.3889
01/05/2026 623,000 2703 2673 2692.6820
Following the settlement of the above transactions, RELX PLC holds 49,796,577
ordinary shares in treasury, and has 1,778,653,801 ordinary shares in issue
(excluding treasury shares). Since 2 January 2026 RELX PLC has purchased
45,688,705 ordinary shares.
Disaggregated information
In accordance with UKLR 9.6.6R and Article 5(1)(b) of Regulation (EU) No
596/2014 as it applies in the UK (the Market Abuse Regulation), detailed
information about the individual purchases is provided on a weekly basis and
for the period above is provided here:
http://www.rns-pdf.londonstockexchange.com/rns/1031D_1-2026-5-5.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/1031D_1-2026-5-5.pdf)
Legal Entity Identifier: 549300WSX3VBUFFJOO66
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSSSIFDIEMSEEI
Copyright 2019 Regulatory News Service, all rights reserved